Glenn Polyak thought he was out of options when his Stage 4 melanoma spread to his brain, until he became only the second ...

A new study shows that TIL therapy, a personalized immunotherapy using a patient's own immune cells, significantly improves ...

About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with ...

OU Health Stephenson Cancer Center in Oklahoma City has started offering tumor-infiltrating lymphocyte (TIL) therapy as a ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Although patients who received tumor-infiltrating lymphocyte (TIL) therapy had favorable overall survival (OS), a significant number who were evaluated to receive lifileucel (Amtagvi) did not get ...

Tumor-infiltrating clonal hematopoiesis increased the risk of disease recurrence or death among patients with cancer. TET2 mutations were the strongest genetic predictor of tumor-infiltrating clonal ...

The lab of Filippo Veglia, Ph.D., at The Wistar Institute has discovered a previously unknown mechanism for how aggressive brain cancers reprogram immune system cells from fighting cancer to enabling ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. It’s not common for cancer surgeons to turn their focus ...

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical ...

Neutrophils are everywhere in the bloodstream and are built for speed, rushing to sites of injury or infection to contain ...

In 2024, tumor-infiltrating lymphocyte (TIL) therapy emerged. It’s the first and only FDA-approved treatment for metastatic melanoma tumors which are non-responsive to other treatments or cannot be ...